Khiron Life Sciences is one of four cannabis stocks in the January Top 40

Two big themes emerge in the January INK Edge Top 40 Stock Report distributed Wednesday morning to Canadian Insider Club members. First, bargain hunters have something to cheer about with eight stocks making the list that rank highly in terms of offering cheap valuations. Secondly, four cannabis-oriented stocks (which we would categorize as growth story stocks) make the list this month. That's a first for the Top 40 as insiders had been more inclined to sell pot stocks than buy. Now, there are a handful where just the opposite is taking place.

Khiron Life Sciences is a Latin America-focused cannabis company

One of the cannabis names in the Top 40 with insider buying is December 14th Morning INK stock Khiron Life Sciences (KHRN) focused on Latin America. As reported in the INK December morning report feature, Khiron develops and commercializes medical cannabis products mainly in Colombia and is active in the research area. Early last month, the company announced it had completed the acquisition of the Latin American Institute of Neurology and the Nervous System ((ILANS). According to Khiron, the ILANS network represents 100,000 patients in Colombia and believes the acquisition will provide a scalable revenue stream with opportunities to introduce medical cannabis to ILANS patients.